MDV3100 is an AR antagonist that blocks androgen binding and prevents nuclear translocation and recruitment of coactivators [24,39]; it has been shown to confer a tumor response in men with CRPC after failure of prior hormonal therapy, with 43% showing a ≥50% PSA response in a phase 1/2 study [40,41]. Here, KLK3 is linked to neoplasm.